Table 2 Disease activity in patients with residual disease activity resulting or not resulting in additional treatment

Age, mean (SD)

53.6 (12.2)

52.6 (10.8)

53.9 (12.7)

0.270

Male/female, n/n

53/37

15/6

38/31

0.167

Disease duration diagnosis mean, (SD)

11.0 (9.2)

10.8 (8.6)

11.2 (9.4)

0.837

On treatment > 6 months, %

92

90

93

0.057

Swollen joints

0 (-0–1)

0 (0–1.5)

0 (0–1)

0.359

SJC of 0, n (%)

63 (70)

13 (62)

50 (72)

SJC of 1, n (%)

8 (9)

3 (14)

5 (7)

SJC of 2, n (%)

5 (6)

2 (10)

3 (4)

SJC of ≥3, n (%)

14 (16)

3 (14)

11 (16)

Tender joints

1 (0–3)

1 (0–2)

1 (0–3)

0.923

TJC of 0, n (%)

36 (40)

7 (33)

29 (42)

TJC of 1, n (%)

16 (18)

8 (38)

8 (12)

TJC of 2, n (%)

12 (13)

2 (10)

10 (15)

TJC of ≥3, n (%)

25 (27)

4 (20)

21 (30)

Number of dactylitic digits

0 (0–0)

0 (0–0)

0 (0–0)

0.310

Dactylitic digits ≥1, n (%)

8 (9)

3 (14)

5 (8)

Number of enthesitis points

0 (0–0)

0 (0–0)

0 (0–0)

0.384

Enthesitis points ≥1, n (%)

16 (18)

5 (24)

11 (16)

VAS physician skin severity

1 (1–3)

2 (1–3.5)

1 (1–2)

0.478

VAS physician overall disease activity

2 (1–4)

3 (2–5)

2 (1–3)

0.007

VAS patient global disease activity

5 (2–7)

6 (3–7)

5 (2–7)

0.157

VAS pt pain

5 (2–7)

6 (3–7)

4 (2–7)

0.225

BASDAI

4.1 (2.5–5.9)

4.2 (2.7–5.8)

3.7 (2.5–5.9)

0.907

cDAPSA remission, n (%)

9 (10)

1 (5)

8 (12)

0.594

cDAPSA low disease activity, n (%)

34 (38)

7 (33)

27 (39)

cDAPSA moderate disease activity, n (%)

35 (39)

11 (52)

23 (33)

cDAPSA high disease activity, n (%)

6 (7)

2 (10)

4 (6)

cDAPSA missing, n (%)

6 (7)

0

6 (9)